{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:29:21Z","timestamp":1784698161641,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1111\/jth.15884","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:28:41Z","timestamp":1663302521000},"page":"2494-2506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-8722","authenticated-orcid":false,"given":"Robert C.","family":"Gosselin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15884_bb0010","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jcp.25.12.1038","article-title":"The partial thromboplastin (cephalin) time test","volume":"25","author":"Poller","year":"1972","journal-title":"J Clin Pathol"},{"issue":"Suppl 1","key":"10.1111\/jth.15884_bb0015","first-page":"S137","article-title":"Controversies in heparin monitoring","volume":"87","author":"Zehnder","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15884_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti\u2010Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.15884_bb0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","article-title":"Therapeutic monitoring of unfractionated heparin\u2014trials and tribulations","volume":"10","author":"Baluwala","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1111\/jth.15884_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1538-7836.2008.03224.x","article-title":"Interlaboratory agreement in the monitoring of unfractionated heparin using the anti\u2010factor Xa\u2010correlated activated partial thromboplastin time","volume":"7","author":"Cuker","year":"2009","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0035","unstructured":"Food and Drug Administration. Lovenox (enoxaparin sodium) injection\u2014Prescribing Information 1993. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/pre96\/20\u2010164_lbl.pdf"},{"key":"10.1111\/jth.15884_bb0040","unstructured":"Food and Drug Administration. Lovenox (enoxaparin sodium) injection\u2014Prescribing Information. 2009. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020164s083lbl.pdf"},{"key":"10.1111\/jth.15884_bb0045","doi-asserted-by":"crossref","first-page":"887S","DOI":"10.1378\/chest.08-0762","article-title":"Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence\u2010based clinical practice guidelines","volume":"133","author":"Monagle","year":"2008","journal-title":"Chest"},{"key":"10.1111\/jth.15884_bb0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5482\/HAMO-17-01-0002","article-title":"Clinical pearls: laboratory assessments of direct oral anticoagulants (DOACS)","volume":"37","author":"Gosselin","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.15884_bb0055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct Oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0065","unstructured":"Centers for Medicare & Medicaid Services. Code Federation Regulation\u2014Part 493\u2014Laboratory Requirements. 1992. Accessed August 11, 2022. https:\/\/www.ecfr.gov\/current\/title\u201042\/chapter\u2010IV\/subchapter\u2010G\/part\u2010493\/subpart\u2010A\/section\u2010493.2"},{"key":"10.1111\/jth.15884_bb0070","unstructured":"International Organization for Standardization. Medical laboratories\u2014requirements for quality and competence (ISO 15189:2012); 2012."},{"key":"10.1111\/jth.15884_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","article-title":"Urgent need to measure effects of direct oral anticoagulants","volume":"134","author":"Weitz","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jth.15884_bb0080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FJC.0000000000000870","article-title":"Therapeutic drug monitoring of direct oral anticoagulants may increase their benefit\u2010risk ratio","volume":"76","author":"Bernier","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/jth.15884_bb0085","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1111\/jth.15104","article-title":"The relationship between DOAC levels and clinical outcomes: the measures tell the tale","volume":"18","author":"Toorop","year":"2020","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0090","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/jth.15248","article-title":"The relationship between DOAC levels and clinical outcomes: the measures tell the tale\u2010response from original authors Lijfering et al","volume":"19","author":"Toorop","year":"2021","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FJC.0000000000000985","article-title":"Is there evidence of benefit of therapeutic drug monitoring for direct oral anticoagulants?\u2010spinning down the centrifuge of enthusiasm","volume":"77","author":"Brunetti","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/jth.15884_bb0100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jth.15245","article-title":"Comment on the article by Toorop et al.: \"the relationship between DOAC levels and clinical outcomes: the measures tell the tale\"","volume":"19","author":"Brunetti","year":"2021","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0105","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1160\/th15-05-0415","article-title":"Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide","volume":"115","author":"Douxfils","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15884_bb0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0125","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/jth.13486","article-title":"Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter\/multiplatform study","volume":"14","author":"Testa","year":"2016","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.thromres.2015.07.018","article-title":"Is thrombin time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study","volume":"136","author":"Lessire","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15884_bb0135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1060028015578451","article-title":"Heparin\u2010calibrated chromogenic anti\u2010Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?","volume":"49","author":"Gosselin","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.15884_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"10.1111\/jth.15884_bb0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2017.05.024","article-title":"Heparin\u2010calibrated chromogenic anti\u2010Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels","volume":"156","author":"Sabor","year":"2017","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15884_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pathol.2022.01.004","article-title":"Prospective cohort study on the use of low molecular weight heparin calibrated anti\u2010Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples","volume":"54","author":"Lim","year":"2022","journal-title":"Pathology"},{"key":"10.1111\/jth.15884_bb0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non\u2010vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1111\/jth.15884_bb0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/2042098618774498","article-title":"Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis","volume":"9","author":"Fava","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"10.1111\/jth.15884_bb0165","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1517\/14740338.2015.1049995","article-title":"Dose tailoring of dabigatran etexilate: obvious or excessive?","volume":"14","author":"Douxfils","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/jth.15884_bb0170","unstructured":"Food and Drug Administration. Andexxa (andexanet alfa)\u2014Prescribing Information; 2022. Accessed August 11, 2022. https:\/\/www.fda.gov\/media\/113279\/download"},{"key":"10.1111\/jth.15884_bb0175","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15884_bb0180","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemostasis"},{"key":"10.1111\/jth.15884_bb0185","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2017.1349749","article-title":"Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures","volume":"17","author":"Vornicu","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/jth.15884_bb0190","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15563650.2020.1743846","article-title":"Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis","volume":"58","author":"Athavale","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1111\/jth.15884_bb0195","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15884_bb0200","unstructured":"Food and Drug Administration. Summary Basis for Regulatory Action\u2014Andexxa\/coagulation factor Xa (recombinant), inactivated\u2010zhzo; 2018. Accessed August 11, 2022. https:\/\/www.fda.gov\/media\/113954\/download"},{"key":"10.1111\/jth.15884_bb0205","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood-2018-06-850396","article-title":"Reversing anti\u2010factor Xa agents and the unmet needs in trauma patients","volume":"132","author":"Hunt","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.15884_bb0210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14712598.2019.1599355","article-title":"Andexanet alfa for the reversal of factor Xa inhibitors","volume":"19","author":"Favresse","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/jth.15884_bb0215","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH14-02-0138","article-title":"Massive human rivaroxaban overdose","volume":"112","author":"Lehmann","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0220","unstructured":"Food and Drug Administration. Praxbind (idarucizumab)\u2014Prescribing Information; 2015. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/761025lbl.pdf"},{"key":"10.1111\/jth.15884_bb0225","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/jth.13706","article-title":"The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran","volume":"15","author":"Simon","year":"2017","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0230","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti\u2010Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0235","unstructured":"Food and Drug Administration. Pradaxa (dabigatran etexilate)\u2014Prescribing Information; 2021. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022512s041lbl.pdf"},{"key":"10.1111\/jth.15884_bb0240","unstructured":"Boehringer Ingelheim Canada Ltd. Dabigatran etexilate\u2014Product Monograph. 2020. Accessed August 11, 2022. https:\/\/docs.boehringer\u2010ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf"},{"key":"10.1111\/jth.15884_bb0245","unstructured":"European Medicines Agency. Pradaxa\u2014Summary of Product Characteristics; 2022. Accessed August 11, 2022. https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/pradaxa\u2010epar\u2010product\u2010information_en.pdf"},{"key":"10.1111\/jth.15884_bb0250","unstructured":"Therapeutic Goods Administration. Dabigatran etexilate\u2014AusPAR; 2015. Accessed August 11, 2022. https:\/\/www.tga.gov.au\/auspar\/auspar\u2010dabigatran\u2010etexilate"},{"key":"10.1111\/jth.15884_bb0255","unstructured":"Therapeutic Goods Administration. Rivaroxaban\u2014AusPAR; 2013. Accessed August 11, 2022. https:\/\/www.tga.gov.au\/auspar\/auspar\u2010rivaroxaban"},{"key":"10.1111\/jth.15884_bb0260","unstructured":"Bayer Inc. Rivaroxaban\u2014Product Monograph; 2021. Accessed August 11, 2022. https:\/\/www.bayer.com\/sites\/default\/files\/2020\u201011\/xarelto\u2010pm\u2010en.pdf"},{"key":"10.1111\/jth.15884_bb0265","unstructured":"European Medicines Agency. Xarelto\u2014Summary of Product Characteristics; 2021. Accessed August 11, 2022. https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/xarelto\u2010epar\u2010product\u2010information_en.pdf"},{"key":"10.1111\/jth.15884_bb0270","unstructured":"Pfizer Canada ULC. Apixaban\u2014Product Monograph; 2019. Accessed August 11, 2022. https:\/\/www.pfizer.ca\/sites\/default\/files\/201910\/ELIQUIS_PM_229267_07Oct2019_Marketed_E.pdf"},{"key":"10.1111\/jth.15884_bb0275","unstructured":"Therapeutic Goods Administration. Apixaban\u2014AusPAR; 2013. Accessed August 11, 2022. https:\/\/www.tga.gov.au\/auspar\/auspar\u2010apixaban"},{"key":"10.1111\/jth.15884_bb0280","unstructured":"European Medicines Agency. Eliquis\u2014Summary of Product Characteristics; 2022. Accessed August 11, 2022. https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/eliquis\u2010epar\u2010product\u2010information_en.pdf"},{"key":"10.1111\/jth.15884_bb0285","unstructured":"Servier Canada Inc. Edoxaban\u2014Product Monograph; 2021. Accessed August 11, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00063796.PDF"},{"key":"10.1111\/jth.15884_bb0290","unstructured":"European Medicines Agency. Lixiana\u2014Summary of Product Characteristics; 2021. Accessed August 11, 2022. https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/lixiana\u2010epar\u2010product\u2010information_en.pdf"},{"key":"10.1111\/jth.15884_bb0295","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti\u2010factor Xa activity, and outcomes: an analysis of data from the randomised, double\u2010blind ENGAGE AF\u2010TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"The Lancet"},{"key":"10.1111\/jth.15884_bb0300","unstructured":"Food and Drug Administration. Eliquis (apixaban)\u2014Prescribing Information; 2021. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202155s034lbl.pdf"},{"key":"10.1111\/jth.15884_bb0305","unstructured":"Food and Drug Administration. Xarelto (rivaroxaban)\u2014Prescribing Information; 2022. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022406Orig1s039,202439Orig1s038correctedlbl.pdf"},{"key":"10.1111\/jth.15884_bb0310","unstructured":"Food and Drug Administration. Savaysa\u2014Prescribing Information; 2021. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206316s017lbl.pdf"},{"key":"10.1111\/jth.15884_bb0315","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-0032-1321954","article-title":"External quality assurance for heparin monitoring","volume":"38","author":"Bonar","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15884_bb0320","unstructured":"Royal College of Pathologists of Australasia Quality Assurance Program (RCPAQAP). Hemostasis; Apixaban (Anti Xa); Dabigatran; Low Molecular Weight Heparin Monitoring; Rivaroxaban (Anti Xa); Unfractionated Heparin Monitoring Survey Reports. St Leonards, NSW Australia; 2021."},{"key":"10.1111\/jth.15884_bb0325","unstructured":"College of American Pathologists (CAP). Surveys and Anatomical Pathology Education Programs. Coagulation, Limited CGL\u2010A; Coagulation Special Testing, CGS4\u2010A; APXBN; RVBN; DBGN Participant Summaries. CAP, Northfield, IL; 2021."},{"key":"10.1111\/jth.15884_bb0330","unstructured":"External quality Control for Assays and Tests (ECAT). ECAT Foundation Report. Survey 2021\u2010A4. The Netherlands; 2021."},{"key":"10.1111\/jth.15884_bb0335","unstructured":"Assessment UKNEQ, Scheme (UKNEQAS) for Blood Coagulation. Report on Exercise 18, Mar 2021; Report on Survey 250. Sep 2021. Sheffield, UK; 2021."},{"key":"10.1111\/jth.15884_bb0340","unstructured":"Food and Drug Administration. Pradaxa (dabigatran etexilate)\u2014Clinical Pharmacology and Biopharmaceutics Review(s); 2020. Accessed August 11, 2022. https:\/\/www.fda.gov\/media\/151627\/download"},{"key":"10.1111\/jth.15884_bb0345","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/ijlh.12870","article-title":"Reduction of the turn\u2010around time for the measurement of rivaroxaban and apixaban: assessment of the performance of a rapid centrifugation method","volume":"40","author":"Dincq","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0350","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11239-016-1431-7","article-title":"Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke","volume":"43","author":"Seiffge","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.15884_bb0355","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0036-1597296","article-title":"Laboratory assessment of direct oral anticoagulants","volume":"43","author":"Douxfils","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15884_bb0360","series-title":"Hemostasis and Thrombosis","first-page":"217","author":"Gosselin","year":"2017"},{"key":"10.1111\/jth.15884_bb0365","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A universal anti\u2010Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15884_bb0370","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ijlh.13692","article-title":"Using a low\u2013molecular weight heparin\u2013calibrated anti\u2013factor Xa assay to assess the concentration of apixaban and rivaroxaban","volume":"44","author":"von Horn","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0375","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40495-020-00232-7","article-title":"Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs)","volume":"6","author":"Rimsans","year":"2020","journal-title":"Curr Pharmacol Rep"},{"key":"10.1111\/jth.15884_bb0380","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/ijlh.13202","article-title":"Assessment of low plasma concentrations of apixaban in the periprocedural setting","volume":"42","author":"Lessire","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1076029616675968","article-title":"Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging","volume":"24","author":"Lessire","year":"2018","journal-title":"Clin Appl Thrombosis\/Hemostasis"},{"key":"10.1111\/jth.15884_bb0390","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.15884_bb0395","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.15884_bb0405","unstructured":"National Institute for Health and Care Excellence. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban; 2022. Accessed September 14, 2022. https:\/\/www.nice.org.uk\/consultations\/1058\/3\/information\u2010about\u2010andexanet\u2010alfa#price"},{"key":"10.1111\/jth.15884_bb0410","unstructured":"Food and Drug Administration. Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs); 2014. Accessed August 11, 2022. https:\/\/www.fda.gov\/media\/89841\/download"},{"key":"10.1111\/jth.15884_bb0415","unstructured":"Food and Drug Administration. Laboratory Developed Tests; 2018. Accessed August 11, 2022. https:\/\/www.fda.gov\/medical\u2010devices\/in\u2010vitro\u2010diagnostics\/laboratory\u2010developed\u2010tests"},{"key":"10.1111\/jth.15884_bb0420","unstructured":"Food and Drug Administration. Classification of the HemosIL Liquid Anti\u2010Xa\u2014DEN190032; 2020. Accessed August 11, 2022. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf19\/DEN190032.pdf"},{"key":"10.1111\/jth.15884_bb0425","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory","volume":"43","author":"Siriez","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0430","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0039-1692700","article-title":"Preanalytical variables in coagulation testing: setting the stage for accurate results","volume":"45","author":"Gosselin","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"10.1111\/jth.15884_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42","author":"Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15884_bb0440","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12676","article-title":"Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants","volume":"6","author":"Favaloro","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.15884_bb0445","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"Adcock","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15884_bb0450","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0455","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high\u2010risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1111\/jth.15884_bb0460","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.pathol.2017.04.011","article-title":"Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing","volume":"49","author":"Favaloro","year":"2017","journal-title":"Pathology"},{"key":"10.1111\/jth.15884_bb0465","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.pathol.2020.05.006","article-title":"Oral anticoagulation therapy: an update on usage, costs and associated risks","volume":"52","author":"Favaloro","year":"2020","journal-title":"Pathology"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622184977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622184977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:36:44Z","timestamp":1761536204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622184977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1538783622184977"],"URL":"https:\/\/doi.org\/10.1111\/jth.15884","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}